Search reports, ask a question, or jump to a page.
The problem
Intervention: Nirsevimab, a long-acting anti-RSV monoclonal antibody administered to infants
Who it was tested with: Infants under 12 months hospitalised with laboratory-confirmed RSV in two Australian jurisdictions with population-wide immunisation programmes.
Experience from people who deliver programmes: stories, case studies and lessons learned. Valuable for understanding how and why, and for spotting what to test next, but not a measure of effect.
"National sentinel hospital-based RSV surveillance was established in 2024, recruiting hospitalised laboratory-confirmed RSV cases and test-negative controls from 22 sites in a national hospital network (FluCAN-PAEDS)." This test-negative case-control design with laboratory confirmation provides robust evidence for estimating vaccine effectiveness by comparing exposure to nirsevimab between hospitalised RSV cases and controls testing negative for RSV.
Study limited to two Australian jurisdictions with population-wide programmes; effectiveness assessment could not be conducted for RSV pregnancy or adult vaccines due to limited uptake; assessment period was only 9 months (April-December 2024).
Across countries and designs
6 studies · 17 countries
